Professor Susanna Kauhanen: Exploring Nordic Breast Reconstruction Practices and the Long-Term Value of Comprehensive Breast Cancer Care

Professor Susanna Kauhanen: Exploring Nordic Breast Reconstruction Practices and the Long-Term Value of Comprehensive Breast Cancer Care

Breast cancer is the most commonly diagnosed malignancy among women worldwide. With continued advances in systemic treatment and surgical techniques, patient survival has improved significantly, making postoperative quality of life and the restoration of physical and psychological well-being increasingly important components of comprehensive breast cancer care. Breast reconstruction is not only a concentrated expression of surgical expertise but also an important means of helping patients return to normal life, making it an integral part of breast cancer prevention and treatment.
Xinghai Forum | Professor Man Li: Advancing Precision and Collaborative Innovation in Comprehensive Cancer Care

Xinghai Forum | Professor Man Li: Advancing Precision and Collaborative Innovation in Comprehensive Cancer Care

To further promote standardized and precision-based cancer treatment, the 7th Dalian Xinghai Medical Forum Academic Conference on Comprehensive Cancer Treatment was jointly organized by the Beijing Cancer Prevention and Control Society and the Beijing Breast Cancer Prevention and Control Society, co-organized by the Oncology Branch of the Dalian Medical Association, and hosted by the Second Affiliated Hospital of Dalian Medical University. The conference was held in Dalian from November 6 to 8, 2026, in a hybrid online and in-person format. Under the theme "Focus on Precision, Collaborate for Innovation," the meeting brought together leading experts from across China in liver cancer, lung cancer, gastrointestinal tumors, breast cancer, lymphoma, gynecologic oncology, immunotherapy, and other fields. Participants delivered presentations on the latest clinical applications and research advances in cancer care. Oncology Frontier invited Professor Man Li of the Second Affiliated Hospital of Dalian Medical University, Chair of the Conference, to introduce the program and highlights of the meeting and share her perspectives on patient education and the research development of young physicians.
2026 IFSC | Professor Ari Melnick: Epigenetic Mechanisms of Stem-Like Plasticity in B-Cell Lymphomas and Targeted Therapeutic Strategies

2026 IFSC | Professor Ari Melnick: Epigenetic Mechanisms of Stem-Like Plasticity in B-Cell Lymphomas and Targeted Therapeutic Strategies

Basic stem cell research, regenerative medicine, cell therapy, and the clinical application of research guidelines are among the most closely watched frontiers in hematology and translational medicine worldwide. With these topics at its core, The 10th International Forum on Stem Cells (IFSC) brought together leading experts and scholars from around the world to explore scientific discoveries and technological innovations, showcase the latest advances in basic, clinical, and translational hematopoietic stem cell research, and promote collaborative innovation across the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute in Spain, to share his latest research findings and academic insights into the mechanisms underlying the acquisition of stem-like plasticity in B-cell lymphomas and emerging targeted therapeutic strategies. The key points are presented below for our readers.
Xinghai Forum | Professor Haibo Wang: Patient-Centered, Multidisciplinary Integration—The “Qingdao Experience” in Breast Specialty Development

Xinghai Forum | Professor Haibo Wang: Patient-Centered, Multidisciplinary Integration—The “Qingdao Experience” in Breast Specialty Development

From November 6 to 8, 2026, the 7th Dalian Xinghai Medical Forum Academic Conference on Comprehensive Cancer Treatment was held with great fanfare. After seven years of development, the Xinghai Forum has grown into an academic platform that brings together multiple disciplines and showcases cutting-edge advances in oncology. During the conference, Professor Haibo Wang of the Affiliated Hospital of Qingdao University shared the “Qingdao experience” in breast specialty development. Professor Wang emphasized the importance of remaining patient-centered and integrating multidisciplinary resources to provide patients with one-stop, precision multidisciplinary team (MDT) diagnosis and treatment services. Breast cancer treatment is not a matter of “fighting alone”; rather, it requires both continuous advancement in surgical techniques and the development of comprehensive systemic medical treatment capabilities to jointly improve the quality of care throughout the breast cancer journey. Professor Wang stressed that the development of specialized disease centers must avoid a department-centered approach and instead maintain a patient-centered focus and multidisciplinary balance. This article summarizes the key points from the interview for our readers.
Roundtable Discussion | Professors Yap Yoon Sim, Man Li, and Janice Tsang: Breaking Down Regional Barriers and Exploring New Paradigms in Breast Cancer Care and Full-Cycle Management Across Asia-Pacific

Roundtable Discussion | Professors Yap Yoon Sim, Man Li, and Janice Tsang: Breaking Down Regional Barriers and Exploring New Paradigms in Breast Cancer Care and Full-Cycle Management Across Asia-Pacific

Innovative breast cancer therapies and high-quality clinical evidence are advancing at an unprecedented pace. However, significant differences persist across regions in biomarker testing standards, drug approval and access timelines, and real-world follow-up systems. These disparities create delays and gaps in translating cutting-edge evidence into clinical practice. At the recently held 2026 Academic Conference on Advances in Breast Cancer Diagnosis and Treatment in Northeast China, Oncology Frontier invited Professor Yap Yoon Sim of the National Cancer Centre Singapore, Professor Man Li of the Second Affiliated Hospital of Dalian Medical University, and Professor Janice Tsang of the Li Ka Shing Faculty of Medicine, The University of Hong Kong, to discuss how the Asia-Pacific region can move beyond academic exchange toward generating shared clinical evidence, and how to bridge the gaps between clinical trials and full-cycle patient management in real-world practice. Drawing on the healthcare systems and clinical experience of their respective regions, the three experts offered valuable perspectives on developing a shared framework for comprehensive breast cancer care across the Asia-Pacific region.
ESMO 2026 Insights | Professor Zhenyu Lin: Two Landmark Studies Led by Professors Tao Zhang and Kaixiong Tao’s Multidisciplinary Team at Wuhan Union Hospital Provide New Evidence from China for Precision Neoadjuvant Treatment of Locally Advanced Rectal Cancer

ESMO 2026 Insights | Professor Zhenyu Lin: Two Landmark Studies Led by Professors Tao Zhang and Kaixiong Tao’s Multidisciplinary Team at Wuhan Union Hospital Provide New Evidence from China for Precision Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Total neoadjuvant therapy (TNT) for locally advanced rectal cancer has become a major focus of research in recent years. A central unresolved question has been whether improvements in pathological complete response (pCR) rates can translate into meaningful survival benefits. At the same time, developing individualized neoadjuvant strategies for patients with different molecular subtypes based on biomarkers remains an urgent clinical priority.
ESMO Oncology Update | Neoadjuvant Enfortumab Vedotin Plus Perioperative Durvalumab Significantly Improves EFS and OS in Patients with MIBC

ESMO Oncology Update | Neoadjuvant Enfortumab Vedotin Plus Perioperative Durvalumab Significantly Improves EFS and OS in Patients with MIBC

The EV-303 and EV-304 studies have expanded the treatment landscape for muscle-invasive bladder cancer (MIBC) by incorporating perioperative enfortumab vedotin plus pembrolizumab into treatment strategies. At the 2026 European Society for Medical Oncology (ESMO) Congress, the phase III VOLGA study reported positive results. In patients with MIBC who were cisplatin-ineligible, neoadjuvant enfortumab vedotin plus perioperative durvalumab, with or without tremelimumab, significantly improved the primary endpoint of event-free survival (EFS) compared with radical cystectomy (RC) alone: median EFS was not reached versus 12.1 months (HR 0.51; 95% CI, 0.38–0.67; P<0.0001).
ESMO Voices from China | Professor Xue Meng: 100% MPR Rate in the First Stage — Exploring a Chemotherapy-Free Neoadjuvant Approach to NSCLC with Sequential SBRT and Iparomlimab/Toripalimab

ESMO Voices from China | Professor Xue Meng: 100% MPR Rate in the First Stage — Exploring a Chemotherapy-Free Neoadjuvant Approach to NSCLC with Sequential SBRT and Iparomlimab/Toripalimab

Platinum-based chemotherapy combined with immunotherapy has become an important perioperative treatment option for resectable non-small cell lung cancer (NSCLC). However, selecting an appropriate regimen remains challenging for patients who are unsuitable for platinum-based chemotherapy. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Xue Meng's team presented a phase II exploratory study investigating stereotactic body radiotherapy (SBRT) followed sequentially by iparomlimab/toviralimab (hereinafter referred to as the “Ipa-Tori combination antibody”), with continued immunotherapy after surgery. In the first-stage results, all nine patients achieved a major pathological response (MPR), representing an MPR rate of 100%. The pathological complete response (pCR) rate was 55.6% (5/9), and all patients underwent R0 resection. These findings provide preliminary support for further investigation, although validation in a larger patient population is needed. Oncology Frontier interviewed Professor Xue Meng about the study design, patient selection, and directions for further validation.